Centogene announces preliminary full year 2023 revenue

Cambridge, mass. and rostock, germany and berlin, jan. 18, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits.
CNTG Ratings Summary
CNTG Quant Ranking